




Systematic Review

# Functional Outcomes of Brolocizumab-Induced Intraocular Inflammation Involving the Posterior Segment—A Meta-Analysis and Systematic Review

Justus G. Garweg<sup>1,2,\*</sup> , Judith Keiper<sup>1,2</sup>, Isabel B. Pfister<sup>1</sup>  and Christin Schild<sup>1</sup> 

<sup>1</sup> Swiss Eye Institute and Clinic for Vitreoretinal Disease, Berner Augenklinik, 3007 Bern, Switzerland; isabel.pfister@augenlinik-bern.ch (I.B.P.); christin.schild@augenlinik-bern.ch (C.S.)

<sup>2</sup> Department of Ophthalmology, Inselspital (Bern University Hospital), University of Bern, 3010 Bern, Switzerland

\* Correspondence: justus.garweg@augenlinik-bern.ch

**Abstract:** Early poor outcomes of intraocular inflammation (IOI) after intravitreal brolocizumab (IVB) have negatively affected the use of brolocizumab in clinical routine. We wished to identify factors related to the treatment details of IOI involving the posterior segment resulting from IVB for neovascular AMD (nAMD), if these were reported in detail. Articles were retrieved from PubMed, Scopus, ClinicalTrials, and CENTRAL using the following search terms: <Brolocizumab> AND <AMD> AND <intraocular inflammation>. The risk of bias was rated using the JBI Critical Appraisal Tool. We included 31 reports (41 patients and 46 eyes). Patients were  $75.9 \pm 8.5$  years, and 58.5% were female. IOI occurred  $41.7 \pm 37.5$  (median 37.0) days after treatment initiation with  $2.0 \pm 1.3$  (1–6) IVB injections. A mean change in visual acuity of  $-14.6 \pm 21.0$  (median  $-6.5$ ) letters was reported. The mean time from first IOI signs to the initiation of any anti-inflammatory treatment was  $3.3 \pm 6.2$  days, with 63% of the patients receiving systemic corticosteroids as standard treatment. Finally, a period effect was observed, with a change in visual acuity of  $-25.3 \pm 27.1$  and  $-2.6 \pm 7.3$  letters in the chronologically first and last third, respectively, of treated eyes (effect size:  $r = 0.71$ ;  $p = 0.006$ ). Functional outcomes markedly improved with increasing experience in managing IOI.

**Keywords:** neovascular age-related macular degeneration; brolocizumab; intraocular inflammation; uveitis; retinal vasculitis; retinal vascular occlusion; treatment outcome



**Citation:** Garweg, J.G.; Keiper, J.; Pfister, I.B.; Schild, C. Functional Outcomes of Brolocizumab-Induced Intraocular Inflammation Involving the Posterior Segment—A Meta-Analysis and Systematic Review. *J. Clin. Med.* **2023**, *12*, 4671. <https://doi.org/10.3390/jcm12144671>

Academic Editor: Masahiko Shimura

Received: 12 May 2023

Revised: 7 July 2023

Accepted: 10 July 2023

Published: 14 July 2023



**Copyright:** © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

The introduction of anti-vascular endothelial growth factor (VEGF) agents for treating exudative or neovascular age-related macular degeneration (nAMD) in 2006 and diabetic maculopathy (DME) in 2010 has dramatically improved the treatment outcomes of these previously blinding diseases [1]. However, existing treatment options (bevacizumab, ranibizumab, and aflibercept) have a considerable rate of incomplete therapeutic responses related to persistent retinal fluid, a high treatment demand, and an unacceptable treatment burden. This incomplete treatment response leads to long-term preventable vision loss as well as the progression of the underlying vascular pathology in AMD [2–7] and DME [8–11]. To some extent, optimizing the treatment strategies has improved the outcomes in nAMD [12–14], but not in DME [15].

A major concern related to long-term anti-VEGF treatment for nAMD, but not for DME, is the occurrence of macular geographic atrophy (MA). Permanent VEGF suppression may contribute to choroidal thinning; contrastingly, persistent subretinal fluid may exert protective effects. Treatment with anti-VEGF agents increases the overall risk of MA [16,17], which partly explains why up to 80% of patients with nAMD often terminate their injection therapy [1].

Brolucizumab is a newer, stronger—regarding its effects on retinal fluid—and longer-acting anti-VEGF agent, which allows a lower rate of incomplete treatment, a reduction in the treatment burden, and an extension of the mean treatment intervals, as demonstrated in two large-scale phase 3 randomized clinical trials (HARRIER and HAWK) [18] as well as early real-life experience [19–31]. Although it has promising therapeutic efficacy, it has been reported to result in intraocular inflammation (IOI) and even severe vision loss [22,32–38]. This has considerably limited its use in real-life clinical settings, which is worsened by the lack of clear guidelines for the management of IOI [39]. Nonetheless, several groups have published guidelines based on expert opinions [13,40–44]. Accordingly, there has been renewed interest in brolucizumab given its therapeutic efficacy [45,46], duration of action, and cost efficacy [23,34,47,48].

Brolucizumab-induced IOI without retinal vascular changes has a mild course in >50% of cases upon the permanent discontinuation of brolucizumab [32,37,49]. The current literature regarding brolucizumab-induced IOI involving the posterior segment is limited to the risk factors for severe vision loss in the absence of early diagnosis and aggressive treatment [38,50]; however, the clinical profile and treatment outcomes of this acute immune-mediated disease remain unclear [51]. Accordingly, we aimed to perform a systematic review and meta-analysis of the clinical profile, time to diagnosis, treatment strategy, and treatment outcomes of brolucizumab-induced IOI involving the posterior segment.

## 2. Patients and Methods

We performed a systematic literature search for articles published until 3 November 2022 on the PubMed, Scopus, ClinicalTrials, and CENTRAL databases using the following key terms: <Brolucizumab OR Beovu> AND <AMD OR macular degeneration OR macula> AND <inflammation OR vasculitis OR occlusion OR uveitis>, without any exclusion criterion, based on the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. The full search strategies are presented in the Supplementary Materials. The reference lists of published reports, meta-analyses, and reviews were screened for suitable original articles. We included all articles related to brolucizumab-induced IOI and its treatment outcomes on a single-patient basis that were written in English, French, or German. We included all articles reporting on cases with age-related macular degeneration (P), which were treated with brolucizumab (I), compared by their visual outcome (C), reported on following intraocular inflammations of the posterior segment, and published as single cases or case series (S) to obtain as much detailed information as possible on therapeutic factors explaining the outcomes of each case according to PICOS criteria. We accepted retrospective and prospective studies as far as they provided a detailed description of the clinical presentation, course, and treatment for single eyes. The exclusion criteria for articles were as follows: summarizing outcomes without referring to single patients; referring to cases without the involvement of the posterior segment; reviews and meta-analyses that summarized previously reported cases; and editorial notes that did not report new observations. All references were managed using the Endnote software. We performed automatic and manual screening for duplicates. Based on the need for a specific search for single patient data in order to address the study questions, we waived study registration.

Two independent researchers screened all the articles based on the inclusion criteria, with discrepancies being resolved in discussions. One author extracted the data from all suitable articles in a two-step process. First, all necessary information based on a coding sheet draft was entered, with additional categories being added as appropriate. Second, missing data were specifically searched for in the research papers. All data entries were confirmed by the first author.

We extracted the following information: general information including identification (first author and publication year), demographic characteristics (age, sex, country, and general and ocular history), timing and type of pretreatment with other anti-VEGF agents,

confirmatory diagnostic tests, treatment of nAMD until the IOI diagnosis, time until IOI treatment, IOI treatment, and treatment outcomes.

We only included peer-reviewed journals to ensure an appropriate level of methodological robustness. Generally, inherent bias could not be avoided given the small number of observations per paper and the multiple confounding factors, including time until IOI diagnosis, treatment initiation, treatment route, and therapy duration. The risk of bias was assessed using the JBI Critical Appraisal Checklist for Case Series, which was found to be medium to high due to missing and inconsistent longitudinal outcome reports (see Supplemental Table S1) [52]. In general, case reports were rated higher for risk of bias than case series since they met less criteria. One has to take into account that the assessment tool was created for case series rather than reports.

### Statistical Analyses

Descriptive statistics were applied since we sought to summarize the existing evidence without a control group. Since the data were not normally distributed, we performed group comparisons using the Mann–Whitney U test. For significant results, we also reported the effect size using the Pearson’s correlation coefficient *r*. All visual acuity results were transformed into early treatment of diabetic retinopathy score (ETDRS) values, where a Snellen decimal best-corrected visual acuity (BCVA) of 1.0 was defined as 85 ETDRS letters. Statistical significance was set at  $p < 0.05$ . Statistical analyses were performed using the SPSS software package 28.0.1 (SPSS, Inc., Chicago, IL, USA) and R (version 3.2.4; R: A language and environment for statistical computing, R Foundation for Statistical Computing, Vienna, Austria, 2016).

### 3. Results

Initially, 568 articles were screened; among them, 31 studies (41 patients; 46 eyes; Figure 1) met the inclusion criteria [21–23,25,27,35,36,50,53–75]. A full list of the included and excluded articles, as well as the extracted data and template, can be obtained upon request from the first author. Figure 1 shows a prismatic flow diagram of the included studies.




Figure 1. PRISMA flow diagram.

### 3.1. Demographics

We included 41 patients (46 eyes) in the analysis (Table 1). Notably, there were no regular descriptions of the baseline clinical findings, evolution of the disease, diagnostic methods, or treatment outcomes. Baseline visual acuity (before the initiation of intravitreal brolocizumab treatment) and evolution of visual acuity were reported in 44 (95.7%) and 41 (89.1%) eyes, respectively.

**Table 1.** Overview of included studies and published cases. n. r.: not reported; R: right eye; L: left eye.

Study Identifier	No. of Patients	Gender (0 = Male, 1 = Female)	Age (Years)	Patient Origin	No. of Eyes	Affected Eye	Treatment-Naïve Eyes (0 = No, 1 = Yes)
Angerer 2020 [53]	1	1	80	n. r.	1	R	0
Barchichat 2022 [54]	1	1	81	n. r.	2	R/L	0
Baumal 2020 [50]	3	1, 1, 1	74, 80, 71	n. r., n. r., n. r.	3	n. r., n. r., L	0, 0, 0
Bilgic 2021 [23]	1	1	71	n. r.	1	L	0
Fukuda 2021 [55]	1	1	77	n. r.	1	L	1
Giunta 2022 [25]	1	n. r.	n. r.	n. r.	1	n. r.	0
Haensli 2021 [22]	3	1, 0, 0	86, 84, 76	Swiss, Swiss, Swiss	3	R, L, L	0, 0, 0
Haug 2020 [56]	1	1	88	caucasian	2	R/L	0, 0
Hikichi 2021 [57]	3	0, 0, 1	72, 82, 94	Japanese	3	R, R, R	0, 0, 0
Iesato 2022 [58]	1	0	72	n. r.	1	R	n. r.
Ito 2022 [27]	2	0, 0	72, 63	Japanese, Japanese	2	n. r., n. r.	1, 1
Iyer 2020 [59]	1	1	76	Caucasian	1	R	0
Jain 2020 [60]	1	1	92	Caucasian	1	L	0
Kataoka 2021 [61]	3	1, 0, 0	52, 68, 71	Japanese, Japanese, Japanese	3	R, R, R	0, 0, 1
Kaupke 2021 [62]	1	n. r.	n. r.	n. r.	1	R	0
Kessler 2022 [63]	1	1	77	Caucasian	2	R/L	0
Kessler 2022 [64]	1	1	76	Caucasian	2	R/L	0
Kondapalli 2020 [65]	1	1	77	n. r.	1	R	0
Kusuhara 2022 [66]	1	1	75	n. r.	1	R	0
Leclaire 2022 [67]	1	0	77	n. r.	1	R	0
Lee 2022 [68]	1	0	71	n. r.	1	L	0
Montesel 2021 [21]	1	1	85	n. r.	1	n. r.	0
Narayanan 2021 [69]	1	1	62	n. r.	1	R	0
Nguyen 2022 [70]	1	0	73	Caucasian	1	R	0
Riedel 2021 [71]	1	1	78	n. r.	2	R/L	0
Rübsam 2022 [72]	1	n. r.	n. r.	n. r.	1	n. r.	1
Saito 2022 [73]	1	1	72	Japanese	1	R	0
Shigemoto 2021 [74]	1	0	71	Caucasian	1	R	0
Singer 2021 [35]	2	1, 0	79, 69	n. r., Asian	2	L, n. r.	1, 1
Witkin 2020 [36]	1	1	92	n. r.	1	R	0
Yoshikawa 2021 [75]	1	1	69	n. r.	1	R	0

The mean age of patients (n = 38; 3 missing patients) was 75.9 ± 8.5 (52–94) years; further, 58.5% (24/38) of the patients were females. Until the occurrence of IOI, the eyes had received one to six (2.0 ± 1.3; median 2.0; IQR 1.0–2.0) intravitreal brolocizumab injections (n = 45). The duration of brolocizumab treatment until IOI development was 41.7 ± 37.5 (median 37.0; IQR 14.0–54.3) days. Moreover, 20 and 25 eyes received only one and two to six brolocizumab injections, respectively (one eye was not reported).

### 3.2. Evolution of Visual Acuity

Table 2A shows the evolution of BCVA. The change in visual acuity from brolocizumab initiation until the last follow up (18–56 days after IOI onset; n = 35) ranged from –66 to +11 (–14.7 ± 21.0; median –6.5; IQR –24.0–0.0) letters. Table 2B displays the number of eyes which experienced vision loss or gain between the onset of IOI and the last follow up. In 5 of 29 cases, we recorded a relevant delay between anterior and posterior segment manifestation.

**Table 2.** Evolution of visual acuity (VA). (A) Evolution of VA over time; (B) change in visual acuity after onset of intraocular inflammation.

(A)						
VA (ETDRS Letters)	n	Mean	SD	Median	IQR (25–75%)	Range
Baseline	44	65.6	17.6	69.9	60–76	20–94
Maximum	17	67.6	15.3	73.9	59–79	35–85
Last	43	50.8	30.5	63.4	15–75	1–94

(B)			
	n (Finding Reported)	% of Reported Eyes (n/N)	% of all Eyes (n = 41) *
Visual loss >15 letters	16	39.0	34.8
Visual loss 6–15 letters	6	14.6	13.0
Stable vision (–5 to +5 letters)	16	39.0	34.8
Visual gain 6–15 letters	3	7.3	6.5

n, number of observations; SD, standard deviation; IQR, interquartile range. Information about visual acuity at baseline was missing for two eyes. Maximum: maximum VA during brolocizumab treatment; \* visual acuity was not reported for two eyes at baseline and for 3 at follow-up.

The mean time from initial IOI symptoms and signs (ocular redness, pain, floaters, blurred vision, photophobia, flashing lights, decline in visual acuity, vitreous cells and/or hemorrhage, retinal vascular sheathing, filling defects and/or leakage, vasculitis, retinal arterial occlusion, retinal ischemia, and optic nerve inflammation) until any anti-inflammatory treatment (topical, intravitreal, oral, intravenous corticosteroid, and sub-Tenon’s capsule triamcinolone acetone injections, as well as vitrectomy) was 3.3 ± 6.2 days (median 0, IQR 0–4.0, n = 41; Table 3).

The time from the initial signs of IOI involving the posterior segment to anti-inflammatory treatment was reported in 37 out of 46 eyes (80.4%); among them, 13 eyes received immediate (same-day) treatment, while the treatment of 14 eyes was initiated within 1 to 7 days, while the remaining 10 were treated between 8 and 28 days. Accordingly, we could not evaluate the impact of time to treatment. Clinical manifestations (Supplemental Table S2) included anterior uveitis in 31/35 eyes (88.6%), vitreal infiltration in 36/39 (92.3%), retinal vascular occlusion in 29/34 (85.3%), retinal vasculitis in 33/39 (84.6%), retinal hemorrhages in 13/16 (81.3%), and macular involvement in 7/12 eyes (58.3%). There was no correlation between symptom duration and macular involvement in seven reported cases.

Treatment initiation in response to intraocular inflammation (Supplemental Table S3) was reported with topical corticosteroids (CSs) in 33/34 eyes (94.1%), intraocular CSs in 5/8 (62.5%), peroral CSs in 19/30 (63.3%), and intravenous ± peroral CSs in 11/13 eyes


(76.9%). Systemic antibiotics were administered in three cases; moreover, none of the patients received intravitreal antibiotics. Vitrectomy was performed in four (8.7%) eyes for different reasons; endophthalmitis was suspected in two (4.3%) eyes at baseline. No systematic treatment patterns were identified in response to intraocular inflammation. The first doses of intravenous and peroral corticosteroids were  $516.0 \pm 437.4$  (median: 375, IQR: 70–1000, range: 40–1000) mg/day and  $48.0 \pm 19.7$  (median: 50, IQR 30–60, range 20–100) mg/day, respectively. There was no difference in visual acuity at any time point between patients who received intravenous and peroral corticosteroids.

**Table 3.** Time interval between last intravitreal brolocizumab injection and the development of intraocular inflammation.

Time (Days) between	n	Mean	SD	Median	IQR (25–75%)	Range
last brolocizumab until first signs of anterior uveitis	30	15.3	12.8	13.5	6.5–21.3	0–56
last brolocizumab until first signs of posterior uveitis	44	19.5	16.9	14.0	7.3–27.0	0–84
last brolocizumab until diagnosis of posterior uveitis	4	22.3	17.6	21.0	8.0–29.5	1–84

Visual outcomes did not differ between eyes treated with systemic (n = 29, 63.0%) and local (n = 7, 15.2%) corticosteroids; however, patients who received local corticosteroids had better visual outcomes 18–56 days after onset of IOI. This suggested that the intensity of treatment depended on the baseline severity of the inflammatory signs and vision loss.

The comparison of the 15 first and last reported cases indicated an improvement in the final visual outcomes following local and systemic corticosteroid treatments. The mean changes in visual acuity in the chronologically first- and last-treated patients were  $-25.3 \pm 27.1$  (median  $-23.1$ , IQR:  $-56$  to  $0$ ;  $p = 0.006$ , effect size:  $r = 0.71$ ) and  $-2.6 \pm 7.3$  (median  $0$ , IQR:  $-8$  to  $0$ ;  $p = 0.148$ ) ETDRS letters, respectively ( $p = 0.019$ , effect size:  $r = 0.63$ ; Figure 2).



**Figure 2.** Evolution of visual acuity in the first and last 15 reported eyes from baseline (beginning of brolocizumab treatment) until end of follow up. Circles: Datapoints for the first 15 reported eyes; Triangles: Datapoints for the last 15 reported eyes; \*: significant difference between the first 15 and the last 15 ( $p = 0.03$ ).

Furthermore, we assessed the potential impact of the number of intravitreal injections prior to the switch to brolocizumab treatment. We observed no difference in baseline BCVA and temporal changes in vision or in the time from brolocizumab initiation to IOI onset (<20 (5–18) injections before switch:  $15.9 \pm 9.5$  (median 14.0, IQR: 8.0 to 21.0) days; >30 (32–94) injections before the switch:  $16.5 \pm 13.1$  (median 11.0, IQR 7.0 to 27.0) days;  $p = 0.78$ ).

#### 4. Discussion

Given the extensive real-world reports on the therapeutic potential of brolocizumab to treat newly diagnosed and insufficiently responsive pre-treated nAMD [20,21,23–25,27,28,30,31,48,49], brolocizumab should be established in our armamentarium for nAMD therapy. However, it involves a considerable risk of IOI ( $\approx 4\%$  (range 0–22%) [30,33,34,76,77]), with roughly 1% of the cases showing severe IOI [33,78]. Most of the reported cases presented a mild clinical picture without permanent vision loss and did not require systemic therapy [24,25,48]. Moreover, many series reported favorable outcomes even in severe cases following early diagnosis and therapy [22,32,33]. One recently published case series of IOI came from an Indian multicenter study and found a mild course requiring only topical corticosteroids in 38%, while the remaining 62% received a systemic treatment. All of these eyes responded well to a combination of topical and systemic corticosteroids but required a recovery time of three months to reach pre-IOI visual acuity; none of the eyes in this series encountered permanent severe vision loss [77]. This tenet has also been reported in a recent systematic review by Wykoff and colleagues [79]. Both papers strongly support our conclusion that with early diagnosis and qualified and timely treatment, severe and permanent vision loss is preventable in the vast majority of cases.

Notably, only 31 papers referring to 47 eyes sufficiently detailed the outcomes of IOI involving posterior segments, which limited the analysis of several parameters, including baseline visual acuity, the presence of macular involvement, the severity of vitreal infiltration, vascular occlusion and vasculitis, the impact of time to treatment, and the treatment route. Nevertheless, we observed a period effect, which indicated progressive learning as demonstrated by mean losses of 25.3 and 3.2 letters in early and recent cases, respectively. This is suggestive of regained interest in brolocizumab at least in cases with high treatment demand [44]. Further, increasing recognition and awareness of brolocizumab-related IOI has improved the diagnostic sensitivity and functional outcomes, as indicated by the Novartis adverse event reporting database, with a retinal vasculitis (RV)/retinal vascular occlusion (RO) reporting rate of 7.5/10,000 injections and a related decline in severe vision loss from 5.9 to 4.1/10,000 injections [80]. IOI with RV/RO was reported in 2.1% of cases, with corresponding severe vision loss in 0.7% of the cases, in a post hoc analysis of HARRIER and HAWK data [38] as well as real-world studies [25,81]. This suggests that IOI involving the posterior segment is a rare event and does not necessarily cause severe vision loss. Our findings demonstrated the therapeutic potential of the early treatment of IOI with posterior segment involvement to improve outcomes [82]. This is consistent with a recent meta-analysis using a random-effects model including 14 randomized controlled trials on 6759 eyes, with no difference in the risk of severe sight-threatening IOI outcomes and retinal vascular occlusion between different anti-VEGF agents. Contrastingly, a six-fold higher incidence of IOI and a 1.6-fold higher incidence of vitreal opacifications was reported with brolocizumab than with aflibercept treatment [78].

In patients with IOI involving the posterior segment, significant vitreal infiltration may obscure the visualization of retinal details [50]. Therefore, wide-field angiography is generally recommended to determine the treatment strategy in the case of suspected IOI with RV/RO [44]. Surprisingly, wide-field angiography was not implemented in most cases to diagnose brolocizumab-induced IOI, which may have contributed to under- and misdiagnosis, as demonstrated by the three suspected endophthalmitis cases in our series. IOI is angiographically associated with retinal vasculitis in >70% of cases, with some of the cases progressing to central vascular occlusion and severe permanent vision

loss [38]. In this meta-analysis, retinal vasculitis was reported in 33 (70%) eyes, which was associated with vascular occlusion in most cases (61.5% of all cases and 82.5% of cases with vascular occlusion). All four patients treated in our institution demonstrated a strong and long-lasting anti-leakage effect of brolocizumab despite severe IOI [39].

Since brolocizumab has only recently been approved for use in DME by the FDA, only one case of retinal arterial occlusion possibly related to brolocizumab has been reported [83], with no cases of DME in our series. Therefore, our findings cannot be readily extrapolated to patients with diabetes; however, this aspect has been addressed in the one-year safety findings obtained from KESTREL and KITE, where no new safety signals were observed [84].

This systematic literature search assessed all articles related to brolocizumab-induced IOI and its treatment outcomes on a single-patient basis. The reporting quality varied remarkably between the single case reports, which unescapably induces heterogeneity bias. For instance, the time from brolocizumab initiation until IOI was reported in 41/46 cases (89%), but the time from initial signs of IOI involving posterior segment to anti-inflammatory treatment was reported in only 37 out of 46 eyes (80.4%). Even visual acuity before the start of brolocizumab was not always reported (82.6%). The absence of such crucial information hindered addressing important points such as the impact of time to treatment.

As indicated by the severity of baseline findings, this analysis of cases reporting treatment outcomes over time may have an inherent reporting bias given that they represent more spectacular cases. Therefore, the real-life outcomes might be even more favorable [80]. This reporting bias towards more severe cases was evidenced by the JBI Critical Appraisal Tool rating; however, the extent of this bias cannot be accurately estimated. Given the negative impact of insufficient disease control on long-term functional outcomes in nAMD [9,47] and the fact that up to 40% of eyes do not achieve disease stability with supportable treatment intervals [5], these cases still require attention from the medical community [24,33,76]. The careful selection of patients who accept the inherent chances and risks, thorough clinical examination prior to each injection in the first year and a minimal treatment interval of 8 weeks after the loading phase, appears to be fundamental for maximal risk mitigation [43]. Finally, given the small number of published cases and the short time of only two years since the publication of the first cases, we felt the registration of this meta-analysis would not be meaningful.

## 5. Conclusions

In conclusion, our findings of a mean vision loss of 3.2 letters in recently reported cases and the downward trend of reported severe functional outcomes justify the use of brolocizumab from a benefit–risk perspective in cases with insufficient responses to other available and approved anti-VEGF drugs, prior to the establishment of systematic evidence or the development of comparably effective and durable new therapies.

**Supplementary Materials:** The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/jcm12144671/s1>. Supplemental Table S1: JBI Critical Appraisal Tool Rating; Supplemental Table S2: Clinical presentation of intraocular inflammation in response to intravitreal brolocizumab injection; Supplemental Table S3: Treatment initiation in response to intraocular inflammation.

**Author Contributions:** J.G.G. and J.K.: conceptualization, data collection and data analysis, and original drafting. I.B.P.: data analysis and original drafting and review. C.S.: project administration and manuscript review. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no funding from any funding agency in the public, commercial, or not-for-profit sectors.

**Institutional Review Board Statement:** For this meta-analysis and systematic review, no ethical approval was requested.



**Informed Consent Statement:** Not applicable for a meta-analysis.

**Data Availability Statement:** Data of this meta-analysis will be made available on qualified request to the corresponding author.

**Conflicts of Interest:** The authors declare they have no financial interests to disclose. No conflicting relationships exist for any author. J.G.G. acts as an advisor to several pharmaceutical companies (AbbVie, Bayer, Novartis, and Roche) and has contributed to several international studies, including those investigating brolocizumab, which had no bearing on the outcomes presented here. The authors received neither direct nor indirect support for this study, nor do they have any conflicting interests regarding the data presented in this report.

## References

1. Finger, R.P.; Puth, M.T.; Schmid, M.; Barthelmes, D.; Guymer, R.H.; Gillies, M. Lifetime Outcomes of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration. *JAMA Ophthalmol.* **2020**, *138*, 1234–1240. [[CrossRef](#)] [[PubMed](#)]
2. Mettu, P.S.; Allingham, M.J.; Cousins, S.W. Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. *Prog. Retin. Eye Res.* **2021**, *82*, 100906. [[PubMed](#)]
3. Chandra, S.; Arpa, C.; Menon, D.; Khalid, H.; Hamilton, R.; Nicholson, L.; Pal, B.; Fasolo, S.; Hykin, P.; Keane, P.A.; et al. Ten-year outcomes of anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration. *Eye.* **2020**, *34*, 1888–1896. [[CrossRef](#)] [[PubMed](#)]
4. Kim, J.H.; Chang, Y.S.; Kim, J.W. Natural course of patients discontinuing treatment for age-related macular degeneration and factors associated with visual prognosis. *Retina* **2017**, *37*, 2254–2261. [[CrossRef](#)]
5. Garweg, J.G.; Gerhardt, C. Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD)—A meta-analysis. *Graefes Arch. Clin. Exp. Ophthalmol.* **2021**, *259*, 2181–2192.
6. Skelly, A.; Taylor, N.; Fasser, C.; Malkowski, J.P.; Goswamy, P.; Downey, L. Patient Preferences in the Management of Wet Age-Related Macular Degeneration: A Conjoint Analysis. *Adv. Ther.* **2022**, *39*, 4808–4820. [[CrossRef](#)]
7. Gomi, F.; Toyoda, R.; Yoon, A.H.; Imai, K. Factors of Anti-Vascular Endothelial Growth Factor Therapy Withdrawal in Patients with Neovascular Age-Related Macular Degeneration: Implications for Improving Patient Adherence. *J. Clin. Med.* **2021**, *10*, 3106. [[CrossRef](#)]
8. Peto, T.; Akerele, T.; Sagkriotis, A.; Zappacosta, S.; Clemens, A.; Chakravarthy, U. Treatment patterns and persistence rates with anti-vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real-world study. *Diabet Med.* **2022**, *39*, e14746. [[CrossRef](#)]
9. Zirpel, J.J.; Pfister, I.B.; Gerhardt, C.; Garweg, J.G. Long-term outcomes of intravitreal therapy for symptomatic diabetic macular oedema in a real-world setting in Switzerland. *Graefes Arch. Clin. Exp. Ophthalmol.* **2021**, *259*, 3569–3578. [[CrossRef](#)]
10. Gao, C.C.; Espinoza Suarez, N.R.; Toloza, F.J.K.; Malaga Zuniga, A.S.; McCarthy, S.R.; Boehmer, K.R.; Yao, L.; Fu, S.; Brito, J.P. Patients' Perspective About the Cost of Diabetes Management: An Analysis of Online Health Communities. *Mayo Clin. Proc. Innov. Qual. Outcomes* **2021**, *5*, 898–906. [[CrossRef](#)]
11. Ehlken, C.; Ziemssen, F.; Eter, N.; Lanzl, I.; Kaymak, H.; Lommatzsch, A.; Schuster, A.K. Systematic review: Non-adherence and non-persistence in intravitreal treatment. *Graefes Arch. Clin. Exp. Ophthalmol.* **2020**, *258*, 2077–2090. [[PubMed](#)]
12. Matonti, F.; Korobelnik, J.F.; Dot, C.; Gualino, V.; Soler, V.; Mrejen, S.; Delyfer, M.N.; Baillif, S.; Strehlo, M.; Gascon, P.; et al. Comparative Effectiveness of Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Managing Neovascular Age-Related Macular Degeneration: A Meta-Analysis. *J. Clin. Med.* **2022**, *11*, 1834. [[CrossRef](#)] [[PubMed](#)]
13. Rosenberg, D.; Deonarain, D.M.; Gould, J.; Sothivannan, A.; Phillips, M.R.; Sarohia, G.S.; Sivaprasad, S.; Wykoff, C.C.; Cheung, C.M.G.; Sarraf, D.; et al. Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: A systematic review and meta-analysis. *Eye* **2023**, *37*, 6–16. [[CrossRef](#)] [[PubMed](#)]
14. Veritti, D.; Sarao, V.; Soppelsa, V.; Danese, C.; Chhablani, J.; Lanzetta, P. Managing Neovascular Age-Related Macular Degeneration in Clinical Practice: Systematic Review, Meta-Analysis, and Meta-Regression. *J. Clin. Med.* **2022**, *11*, 325. [[PubMed](#)]
15. Garweg, J.G.; Štefanickova, J.; Hoyng, C.; Niesen, T.; Schmelter, T.; Leal, S.; Sivaprasad, S. Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial. *Adv. Ther.* **2022**, *39*, 2701–2716. [[CrossRef](#)]
16. Foss, A.; Rotsos, T.; Empselidis, T.; Chong, V. Development of Macular Atrophy in Patients with Wet Age-Related Macular Degeneration Receiving Anti-VEGF Treatment. *Ophthalmologica* **2022**, *245*, 204–217. [[CrossRef](#)]
17. Garweg, J.G. Atrophy of the macula in the context of its wet, age-related degeneration: An inescapable consequence of anti-VEGF therapy? *Ophthalmologie* **2016**, *113*, 1036–1045. [[CrossRef](#)]
18. Regillo, C.; Singh, R.; Hamilton, R.; Gedif, K.; Best, C.; Koh, A.; Holz, F.G. Fluid control in neovascular age-related macular degeneration with brolocizumab: An analysis of the HAWK and HARRIER phase 3 trials. *Ophthalmologica* **2022**, *245*, 403–412. [[CrossRef](#)]

19. Abdin, A.D.; Aljundi, W.; El Jawhari, K.; Suffo, S.; Weinstein, I.; Seitz, B. First Year Real Life Experience with Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration. *Front. Pharmacol.* **2022**, *13*, 860784. [[CrossRef](#)]
20. Book, M.; Ziegler, M.; Rothaus, K.; Faatz, H.; Gutfleisch, M.; Spital, G.; Lommatzsch, A.; Pauleikhoff, D. Real-life experiences with Brolucizumab in recalcitrant neovascular age-related macular degeneration. *Ophthalmologe* **2022**, *119*, 258–264. [[CrossRef](#)]
21. Montesel, A.; Bucolo, C.; Sallo, F.B.; Eandi, C.M. Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice. *Front. Pharmacol.* **2021**, *12*, 720345. [[CrossRef](#)]
22. Haensli, C.; Pfister, I.B.; Garweg, J.G. Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes. *J. Clin. Med.* **2021**, *10*, 2666. [[CrossRef](#)]
23. Bilgic, A.; Kodjikian, L.; March de Ribot, F.; Vasavada, V.; Gonzalez-Cortes, J.H.; Abukashabah, A.; Sudhalkar, A.; Mathis, T. Real-World Experience with Brolucizumab in Wet Age-Related Macular Degeneration: The REBA Study. *J. Clin. Med.* **2021**, *10*, 2758. [[CrossRef](#)] [[PubMed](#)]
24. Chakraborty, D.; Maiti, A.; Sheth, J.U.; Mondal, S.; Boral, S.; Nandi, K.; Sinha, T.K.; Das, A. Brolucizumab in Neovascular Age-Related Macular Degeneration-Indian Real-World Experience: The BRAILLE Study-Fifty-Two-Week Outcomes. *Clin. Ophthalmol.* **2022**, *16*, 4303–4313. [[CrossRef](#)] [[PubMed](#)]
25. Giunta, M.; Gauvin Meunier, L.P.; Nixon, D.; Steeves, J.; Noble, J. Early Canadian Real-World Experience with Brolucizumab in Anti-Vascular Endothelial Growth Factor-Experienced Patients with Neovascular Age-Related Macular Degeneration: A Retrospective Chart Review. *Clin. Ophthalmol.* **2022**, *16*, 2885–2894. [[CrossRef](#)] [[PubMed](#)]
26. Hoshino, J.; Matsumoto, H.; Mukai, R.; Nakamura, K.; Akiyama, H. Intravitreal Aflibercept versus Brolucizumab for Treatment-Naive Neovascular Age-Related Macular Degeneration with Type 1 Macular Neovascularization: Comparison of Short-Term Outcomes. *Ophthalmologica* **2022**, *245*, 413–420. [[CrossRef](#)] [[PubMed](#)]
27. Ito, A.; Maruyama-Inoue, M.; Kitajima, Y.; Ikeda, S.; Inoue, T.; Kadonosono, K. One-year outcomes of intravitreal brolucizumab injections in patients with polypoidal choroidal vasculopathy. *Sci. Rep.* **2022**, *12*, 7987. [[CrossRef](#)]
28. Khanani, A.M.; Brown, D.M.; Jaffe, G.J.; Wykoff, C.C.; Adiguzel, E.; Wong, R.; Meng, X.; Heier, J.S. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid. *Ophthalmology* **2022**, *129*, 974–985. [[CrossRef](#)]
29. Kitajima, Y.; Maruyama-Inoue, M.; Ikeda, S.; Ito, A.; Inoue, T.; Yanagi, Y.; Kadonosono, K. Short-term outcomes of switching to brolucizumab in Japanese patients with neovascular age-related macular degeneration. *Jpn. J. Ophthalmol.* **2022**, *66*, 511–517. [[CrossRef](#)]
30. Matsumoto, H.; Hoshino, J.; Mukai, R.; Nakamura, K.; Akiyama, H. One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization. *Sci. Rep.* **2022**, *12*, 8195. [[CrossRef](#)]
31. Ueda-Consolvo, T.; Taniguchi, A.; Numata, A.; Oiwake, T.; Nakamura, T.; Ishida, M.; Yanagisawa, S.; Hayashi, A. Switching to brolucizumab from aflibercept in age-related macular degeneration with type 1 macular neovascularization and polypoidal choroidal vasculopathy: An 18-month follow-up study. *Graefes Arch. Clin. Exp. Ophthalmol.* **2023**, *261*, 345–352. [[CrossRef](#)] [[PubMed](#)]
32. Stepanov, A.; Studnicka, J.; Veith, M.; Nemec, P.; Vyslouzilova, D.; Koubek, M.; Nemcansky, J. Incidence of adverse events after loading phase of the brolucizumab therapy of neovascular AMD: Real-life evidence in the Czech Republic. *Eur. J. Ophthalmol.* **2023**, *33*, 1097–1104. [[CrossRef](#)] [[PubMed](#)]
33. Bauman, C.R.; Sørensen, T.L.; Karcher, H.; Freitas, R.L.; Becher, A.; Balez, S.; Clemens, A.; Singer, M.; Kodjikian, L. Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies. *Acta Ophthalmol.* **2022**, *101*, 123–139. [[CrossRef](#)] [[PubMed](#)]
34. Murray, J.E.; Gold, A.S.; Latiff, A.; Murray, T.G. Brolucizumab. *Evaluation of Compassionate Use of a Complex Anti-VEGF Therapy.* *Clin. Ophthalmol.* **2021**, *15*, 4731–4738.
35. Singer, M.; Albini, T.A.; Seres, A.; Bauman, C.R.; Parikh, S.; Gale, R.; Kaiser, P.K.; Lobach, I.; Feltgen, N.; Joshi, M.R.; et al. Clinical Characteristics and Outcomes of Eyes with Intraocular Inflammation after Brolucizumab: Post Hoc Analysis of HAWK and HARRIER. *Ophthalmol. Retin.* **2022**, *6*, 97–108. [[CrossRef](#)]
36. Witkin, A.J.; Hahn, P.; Murray, T.G.; Arevalo, J.F.; Blinder, K.J.; Choudhry, N.; Emerson, G.G.; Goldberg, R.A.; Kim, S.J.; Pearlman, J.; et al. Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab. *J. Vitro. Dis.* **2020**, *4*, 269–279. [[CrossRef](#)]
37. Witkin, A.J.; Hahn, P.; Murray, T.G.; Arevalo, J.F.; Blinder, K.J.; Choudhry, N.; Emerson, G.G.; Goldberg, R.A.; Kim, S.J.; Pearlman, J.; et al. Brolucizumab-associated intraocular inflammation in eyes without retinal vasculitis. *J. Vitro. Dis.* **2021**, *5*, 326–332. [[CrossRef](#)]
38. Monés, J.; Srivastava, S.K.; Jaffe, G.J.; Tadayoni, R.; Albini, T.A.; Kaiser, P.K.; Holz, F.G.; Korobelnik, J.F.; Kim, I.K.; Prunte, C.; et al. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER. *Ophthalmology* **2021**, *128*, 1050–1059. [[CrossRef](#)]
39. Garweg, J.G.; Hänsli, C. Pitfalls in the Interpretation of Intraocular Inflammation in Response to Intravitreal Brolucizumab Injection. *Ocul. Immunol. Inflamm.* **2023**, *31*, 249–251. [[CrossRef](#)]
40. Fonollosa, A.; Gallego-Pinazo, R.; Sararols, L.; Adán, A.; López-Gálvez, M.; Figueroa, M.S. Guidance on brolucizumab management recommendations. *Arch. Soc. Esp. Ophthalmol. (Engl. Ed.)* **2022**, *97*, 626–638. [[CrossRef](#)]

41. Kilmartin, D.J. Literature review and proposal of best practice for ophthalmologists: Monitoring of patients following intravitreal brolocizumab therapy. *Ir. J. Med. Sci.* **2022**, *192*, 447–456. [[CrossRef](#)]
42. Bauml, C.R.; Bodaghi, B.; Singer, M.; Tanzer, D.J.; Seres, A.; Joshi, M.R.; Feltgen, N.; Gale, R. Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and Vascular Occlusion after Brolocizumab Treatment. *Ophthalmol. Retina* **2021**, *5*, 519–527. [[CrossRef](#)] [[PubMed](#)]
43. Holz, F.G.; Iida, T.; Maruko, I.; Sadda, S.R. A consensus on risk mitigation for brolocizumab in neovascular age-related macular degeneration: Patient Selection, Evaluation, and Treatment. *Retina* **2022**, *42*, 1629–1637. [[CrossRef](#)] [[PubMed](#)]
44. Garweg, J.G.; Blum, C.A.; Copt, R.P.; Eandi, C.M.; Hatz, K.; Prunte, C.F.; Seelig, E.; Somfai, G.M. Brolocizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects. *Ophthalmol. Ther.* **2023**, *12*, 639–655. [[CrossRef](#)] [[PubMed](#)]
45. Ferrante, N.; Ritrovato, D.; Bitonti, R.; Furneri, G. Cost-effectiveness analysis of brolocizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy. *BMC Health Serv. Res.* **2022**, *22*, 573. [[CrossRef](#)] [[PubMed](#)]
46. Yu, J.S.; Carlton, R.; Agashivala, N.; Hassan, T.; Wykoff, C.C. Brolocizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: A cost-effectiveness analysis. *J. Manag. Care Spec. Pharm.* **2021**, *27*, 743–752. [[CrossRef](#)]
47. Ghanchi, F.; Bourne, R.; Downes, S.M.; Gale, R.; Rennie, C.; Tapply, I.; Sivaprasad, S. An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma. *Eye* **2022**, *36*, 1154–1167. [[CrossRef](#)]
48. Bulirsch, L.M.; Saßmannshausen, M.; Nadal, J.; Liegl, R.; Thiele, S.; Holz, F.G. Short-term real-world outcomes following intravitreal brolocizumab for neovascular AMD: SHIFT study. *Br. J. Ophthalmol.* **2022**, *106*, 1288–1294. [[CrossRef](#)]
49. Enríquez, A.B.; Bauml, C.R.; Crane, A.M.; Witkin, A.J.; Lally, D.R.; Liang, M.C.; Enríquez, J.R.; Eichenbaum, D.A. Early Experience With Brolocizumab Treatment of Neovascular Age-Related Macular Degeneration. *JAMA Ophthalmol.* **2021**, *139*, 441–448. [[CrossRef](#)]
50. Bauml, C.R.; Spaide, R.F.; Vajzovic, L.; Freund, K.B.; Walter, S.D.; John, V.; Rich, R.; Chaudhry, N.; Lakhanpal, R.R.; Oellers, P.R.; et al. Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolocizumab. *Ophthalmology* **2020**, *127*, 1345–1359. [[CrossRef](#)]
51. Schmouder, R.L.M.B.; Karle, A.; Glick, J.; Rubic-Schneider, T.; Ledieu, D.; Watts, J.; Brees, D. Immunologic features of Beovu<sup>®</sup>-associated retinal vasculitis/retinal vascular occlusion. In Proceedings of the EURETINA 2021 Virtual Congress, Virtual, 9–12 September; 2021.
52. Munn, Z.; Barker, T.H.; Moola, S.; Tufanaru, C.; Stern, C.; McArthur, A.; Stephenson, M.; Aromataris, E. Methodological quality of case series studies: An introduction to the JBI critical appraisal tool. *JBI Evid. Synth.* **2020**, *18*, 2127–2133. [[CrossRef](#)]
53. Angerer, M.P.M.; Neuburger, M.; Hille, K.; Horn, P.C. Vaso-occlusive retinitis following intravitreal injection of brolocizumab. *Ophthalmologie* **2021**, *118*, 1048–1050. [[CrossRef](#)] [[PubMed](#)]
54. Barchichat, I.; Thiel, M.; Job, O.; Schmid, M. Bilateral blindness after uneventful brolocizumab injection for macular degeneration. *BMC Ophthalmol.* **2022**, *22*, 80. [[CrossRef](#)] [[PubMed](#)]
55. Fukuda, Y.; Sakurada, Y.; Matsubara, M.; Hasebe, Y.; Sugiyama, A.; Kikushima, W.; Kashiwagi, K. Comparison of Outcomes between 3 Monthly Brolocizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy. *Biomedicines.* **2021**, *9*, 1164. [[CrossRef](#)] [[PubMed](#)]
56. Haug, S.J.; Hien, D.L.; Uludag, G.; Ngoc, T.T.T.; Lajevardi, S.; Halim, M.S.; Sepah, Y.J.; Do, D.V.; Khanani, A.M. Retinal arterial occlusive vasculitis following intravitreal brolocizumab administration. *Am. J. Ophthalmol. Case Rep.* **2020**, *18*, 100680. [[CrossRef](#)]
57. Hikichi, T. Three Japanese cases of intraocular inflammation after intravitreal brolocizumab injections in one clinic. *Jpn. J. Ophthalmol.* **2021**, *65*, 208–214. [[CrossRef](#)]
58. Iesato, Y.; Hirano, T.; Yoshida, N. Early Recovery from Vasculitis after Brolocizumab with Prompt Steroid Treatment. *Ophthalmol. Retina* **2022**, *6*, 325. [[CrossRef](#)]
59. Iyer, P.G.; Peden, M.C.; Suñer, I.J.; Patel, N.; Dubovy, S.R.; Albini, T.A. Brolocizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: A clinicopathologic case study. *Am. J. Ophthalmol. Case Rep.* **2020**, *20*, 100989. [[CrossRef](#)]
60. Jain, A.; Chea, S.; Matsumiya, W.; Halim, M.S.; Yaşar, Ç.; Kuang, G.; Sepah, Y.J.; Khanani, A.M.; Do, D.V.; Nguyen, Q.D. Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolocizumab administrations. *Am. J. Ophthalmol. Case Rep.* **2020**, *18*, 100687. [[CrossRef](#)]
61. Kataoka, K.; Horiguchi, E.; Kawano, K.; Ushida, H.; Nakano, Y.; Ito, Y.; Terasaki, H. Three cases of brolocizumab-associated retinal vasculitis treated with systemic and local steroid therapy. *Jpn. J. Ophthalmol.* **2021**, *65*, 199–207. [[CrossRef](#)]
62. Kaupke, N.; Stübiger, N.; Dulz, S.; Spitzer, M.S.; Casagrande, M. Acute unilateral loss of vision after intravitreal injection of a VEGF inhibitor. *Ophthalmologie* **2021**, *118*, 1276–1279. [[CrossRef](#)] [[PubMed](#)]
63. Kessler, L.J.; Mayer, C.S.; Son, H.S.; Auffarth, G.U.; Khoramnia, R. Bilateral vasculitis following intravitreal brolocizumab injection. *Ophthalmologie* **2022**, *119*, 93–97. [[CrossRef](#)]
64. Kessler, L.J.; Mayer, C.S.; Bagautdinov, D.; Ceglowska, K.; Auffarth, G.U.; Khoramnia, R. Bilateral Vasculitis after Single Intravitreal Brolocizumab Injection. *Klin. Monbl. Augenheilkd.* **2022**, *239*, 196–201. [[PubMed](#)]
65. Kondapalli, S.S.A. Retinal Vasculitis After Administration of Brolocizumab Resulting in Severe Loss of Visual Acuity. *JAMA Ophthalmol.* **2020**, *138*, 1103–1104. [[CrossRef](#)] [[PubMed](#)]

66. Kusuhara, S.; Kim, K.W.; Miki, A.; Nakamura, M. Angiographic findings before and after the onset of brolocizumab-associated retinal vascular occlusion and intraocular inflammation. *Am. J. Ophthalmol. Case Rep.* **2022**, *26*, 101521. [[CrossRef](#)]
67. Leclaire, M.D.; Lauermaun, J.; Alten, F.; Eter, N. Intraocular inflammation with occlusive retinal vasculitis following intravitreal injection of brolocizumab. *Ophthalmologie* **2022**, *119*, 296–299. [[CrossRef](#)]
68. Lee, E.K.; Oh, B.L.; Yoon, C.K.; Park, U.C. Swept-source optical coherence tomography angiography of retinal occlusive vasculitis following brolocizumab administration: A case report. *BMC Ophthalmol.* **2022**, *22*, 244. [[CrossRef](#)]
69. Narayanan, R.; Tyagi, M.; Gupta, S.R.; Nayaka, A.; Jayadev, C. Immediate onset of sterile endophthalmitis with hypopyon after intravitreal Brolocizumab in a case of polypoidal choroidal vasculopathy. *Indian J. Ophthalmol.* **2021**, *69*, 469–470. [[CrossRef](#)]
70. Nguyen, H.V.; Li, A.S.; Silva, A.R.; Leng, T. Ocular adverse events following intravitreal brolocizumab for neovascular age-related macular degeneration at a single tertiary care center. *Eur. J. Ophthalmol.* **2022**, *32*, 2747–2751. [[CrossRef](#)]
71. Riedel, A.M.; Lackerbauer, C.; Lohmann, C.P.; Ulbig, M. Bilateral occlusive vasculitis after intravitreal injection of brolocizumab in neovascular age-related macular degeneration. *Ophthalmologie* **2022**, *119*, 75–78. [[CrossRef](#)]
72. RübSam, A.; Rau, S.; Pilger, D.; Zeitz, O.; Joussem, A.M. Early OCT Angiography Changes of Macular Neovascularization in Patients with Exudative AMD Treated with Brolocizumab in a Real-World Setting. *J. Ophthalmol.* **2022**, *2022*, 2659714. [[CrossRef](#)]
73. Saito, M.; Kobori, H.; Nozuki, N.; Kogawa, S.; Kudo, A. A case of intraocular inflammation after intravitreal brolocizumab injection monitored by laser flare-cell photometer. *Am. J. Ophthalmol. Case Rep.* **2022**, *28*, 101727. [[CrossRef](#)]
74. Shigemoto, Y.; Sakurada, Y.; Fukuda, Y.; Matsubara, M.; Parikh, R.; Kashiwagi, K. The combination therapy of subtenon triamcinolone acetonide injection and intravitreal brolocizumab for brolocizumab-related intraocular inflammation. *Medicine* **2021**, *100*, e27580. [[CrossRef](#)]
75. Yoshikawa, Y.; Kumagai, T.; Shinoda, K. Vitreous Noise on Optical Coherence Tomography as an Early Finding of Brolocizumab-Related Intraocular Inflammation. *Case Rep. Ophthalmol.* **2021**, *12*, 797–803. [[CrossRef](#)] [[PubMed](#)]
76. Boltz, A.; Radunsky, K.; Weingessel, B.; Vécsei-Marlovits, V.P. Brolocizumab for pre-treated patients with choroidal neovascularization and signs of tachyphylaxis to aflibercept and bevacizumab. *Graefes Arch. Clin. Exp. Ophthalmol.* **2022**, *260*, 2561–2566. [[CrossRef](#)] [[PubMed](#)]
77. Chakraborty, D.; Mondal, S.; Sengupta, S.; Abbas, Z.; Chandra, K.; Boral, S.; Aniruddha, M.; Sangeeta, R.; Angshuman, M.; Arnab, D.; et al. Incidence, clinical features, risk factors, and outcomes of intraocular inflammation following brolocizumab in Indian eyes –A multicentric study. *Indian J. Ophthalmol.* **2023**, *71*, 1979–1985. [[CrossRef](#)]
78. Patil, N.S.; Dhoot, A.S.; Popovic, M.M.; Kertes, P.J.; Muni, R.H. Risk of intraocular inflammation after injection of antivascular endothelial growth factor agents: A Meta-analysis. *Retina* **2022**, *42*, 2134–2142. [[CrossRef](#)] [[PubMed](#)]
79. Wykoff, C.C.; Matsumoto, H.; Barakat, M.R.; Karcher, H.; Lozama, A.; Mayhook, A.; Oshagbemi, O.A.; Zorina, O.; Hassan, T.S.; Khanani, A.M.; et al. Retinal Vasculitis or Vascular Occlusion after Brolocizumab for Neovascular Age-Related Macular Degeneration: A Systematic Review of Real-World Evidence. *Retina* **2023**, *43*, 1051–1063. [[CrossRef](#)]
80. Igwe, F.; Lodha, A.; Ravindran, A. Trends in the Cumulative Post-Marketing Reporting Rates of Retinal Vasculitis and/or Retinal Vascular Occlusion and Associated Vision Loss with Brolocizumab. *Ophthalmol. Ther.* **2023**, *12*, 593–598. [[CrossRef](#)]
81. Khanani, A.M.; Zarbin, M.A.; Barakat, M.R.; Albin, T.A.; Kaiser, P.K.; Guruprasad, B.; Agashivala, N.; Yu, J.S.; Wykoff, C.C.; MacCumber, M.W. Safety Outcomes of Brolocizumab in Neovascular Age-Related Macular Degeneration: Results from the IRIS Registry and Komodo Healthcare Map. *JAMA Ophthalmol.* **2022**, *140*, 20–28. [[CrossRef](#)]
82. Mukai, R.; Matsumoto, H.; Akiyama, H. Risk factors for emerging intraocular inflammation after intravitreal brolocizumab injection for age-related macular degeneration. *PLoS ONE* **2021**, *16*, e0259879. [[CrossRef](#)] [[PubMed](#)]
83. Hirano, T.; Toriyama, Y.; Takahashi, Y.; Hoshiyama, K.; Murata, T. Retinal arterial occlusive vasculitis after multiple intravitreal brolocizumab injections for diabetic macular edema. *Am. J. Ophthalmol. Case Rep.* **2023**, *29*, 101788. [[CrossRef](#)] [[PubMed](#)]
84. Brown, D.M.; Emanuelli, A.; Bandello, F.; Barranco, J.J.E.; Figueira, J.; Souied, E.; Wolf, S.; Gupta, V.; Ngah, N.F.; Liew, G.; et al. KESTREL and KITE: 52-Week Results from Two Phase III Pivotal Trials of Brolocizumab for Diabetic Macular Edema. *Am. J. Ophthalmol.* **2022**, *238*, 157–172. [[CrossRef](#)] [[PubMed](#)]

**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.